IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

ImmunoGen, Inc.49 enrolled

Overview

The purpose of this study is to test the safety and tolerability of IMGN529 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL).

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Lymphoma, Non-Hodgkin Chronic Lymphocytic Leukemia

Interventions

IMGN529DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Relapsed or refractory NHL including tumor types: Follicular lymphoma (FL), marginal zone lymphoma (MZL)/mucosa-associated lymphoid tissue (MALT), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL). * Adequate organ function * ECOG ≤ 2 * Recovered or stabilized from prior treatments. Exclusion Criteria: * Allogeneic stem cell transplantation * Pregnant or lactating females * Known central nervous system, meningeal or epidural disease including brain metastases

Locations (7)

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Memorial Sloan-Kettering Cancer Center

New York, New York, United States

Ohio State University

Columbus, Ohio, United States

Sarah Cannon Research Institute

Nashville, Tennessee, United States

Outcomes

Primary Outcomes

Occurrence of dose limiting toxicities

Time frame: During study

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.